1st human trial to test LBL-034 for hard-to-treat myeloma in US, China
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to destroy cancer cells, in people with relapsed or refractory multiple myeloma in the U.S. and China. Leads Biolabs has received approval to launch the…